PP
SPRO icon

PFS Partners’s Spero Therapeutics SPRO Stock Holding History

PFS Partners’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50
Closed -$86 – 469
2024
Q1 		$86 Hold
50
– – ﹤0.01% 458
2023
Q4 		$74 Sell
50
-200
-80% -$238 ﹤0.01% 458
2023
Q3 		$303 Hold
250
– – ﹤0.01% 445
2023
Q2 		$358 Hold
250
– – ﹤0.01% 461
2023
Q1 		$358 Hold
250
– – ﹤0.01% 375
2022
Q4 		$433 Hold
250
– – ﹤0.01% 360
2022
Q3 		$500 Hold
250
– – ﹤0.01% 345
2022
Q2 		$186 Hold
250
– – ﹤0.01% 348
2022
Q1 		$2.17K Hold
250
– – ﹤0.01% 306
2021
Q4 		$4K Buy
+250
New +$3.97K ﹤0.01% 276

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PFS Partners's SPRO Position: Q2 2024 in Review

PFS Partners sold out of Spero Therapeutics (SPRO) in Q2 2024, closing a stake of 50 shares — an estimated $86 sold.

PFS Partners first reported a position in SPRO in Q4 2021 and held it in 10 quarters. The position peaked at $4K in Q4 2021. 48 funds tracked by Wall St. Rank hold SPRO as of Q2 2024.

  • PFS Partners reported no remaining Spero Therapeutics position as of Q2 2024 after selling out during the quarter.
  • PFS Partners sold 50 Spero Therapeutics shares in Q2 2024, an estimated $86.
  • PFS Partners first reported a position in Spero Therapeutics in Q4 2021 and held it in 10 quarters.
  • PFS Partners's Spero Therapeutics position peaked at $4K in Q4 2021.
  • 48 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2024.

Based on PFS Partners's 13F filing for Q2 2024, filed 25 Jul 2024.